Biochem/physiol Actions

TMI-1 (WAY-171318) is potent inhibitor of disintegrin metalloenzyme 17 (ADAM17) also known as the tumor necrosis factor-α (TNF-α) converting enzyme (TACE), and matrix metalloprotease (MMP). TMI-1 potently inhibits LPS-induced TNF-α secretion in human primary monocytes, and human whole blood. TMI-1 selectively induces caspase-dependent apoptosis in triple negative (TN) and ERBB2-overexpressing breast tumor cell lines.

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Sold for research purposes under agreement from Pfizer Inc.

Other Notes

This compound was developed by Pfizer for Cytokines & Growth Factors research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5 mg in glass bottle